At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them
Executive Summary
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
You may also be interested in...
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.